BGI overcomes hostile bid to make milestone public company purchase

0
1647
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

China’s growing appetite for overseas high-tech was showcased in the first acquisition of a US public company by a Chinese corporation, a lawyer involved in the deal said.

But not without a fight. Wendy Pan, a Shanghai-based partner at O’Melveny & Myers, told China Business Law Journal the deal had to clear bureaucratic hurdles from both countries and overcome an aggressive bid from a rival company to succeed.

story_1_picChinese genomics company BGI-Shenzhen acquired the Nasdaq-listed Complete Genomics through a cash tender offer, followed by a short-form merger that became effective on 18 March. O’Melveny & Myers acted for BGI. The O’Melveny team was led by Pan and the firm’s Silicon Valley-based partner Paul Scrivano.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link